The Pomp Podcast
#495 James Peyer on Longevity and Curing Cancer
- The nine hallmarks of aging are nine categories of molecular damage (DNA mutations, telomere shortening, epigenetic loss, cellular senescence, mitochondrial dysfunction, stem cell exhaustion, chronic inflammation, and others) that accumulate over decades before diseases manifest.
- Molecular damage occurs silently during healthy years, 10–30 years before diagnosis; prevention and early reversal are scientifically easier than treating advanced disease but harder to implement in healthcare systems designed around reaction.
- Healthspan (quality-adjusted healthy years) matters more than lifespan; extending only unhealthy end-of-life years provides no benefit, but mouse and human data show that interventions extend healthy periods while decline duration remains constant.
- Cambrian's distributed drug discovery company (DISCO) model absorbs university research projects into one umbrella, making funding and development decisions based on science merit rather than hype, enabling simultaneous work on multiple longevity-targeting assets.
- Sensei, a cancer vaccine company using viral-vector technology to trigger immune responses against tumor cells, exemplifies Cambrian's dual-value thesis: treating stage-four cancers now while building toward preventative and early-detection applications via liquid biopsy.
- Regulatory paradigm shift needed: FDA currently requires 30–40 years to validate aging-slowing drugs, but surrogate biomarkers (like cholesterol for statins) could enable approval and long-term follow-up validation for preventative therapies.